Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT00835120 Completed - Metabolic Syndrome Clinical Trials

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance. Subjects who experience a partial or full response will have the option of continuing in an acute continuation phase lasting up to 12 weeks. The extension phase will allow assessment of the safety and tolerability of pioglitazone during the acute continuation period.

NCT ID: NCT00826774 Completed - Obesity Clinical Trials

Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)

Power-UP
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare three methods of achieving weight loss in primary care medical practice. The study will be conducted in six primary care practices. Weight management will be provided to a total of 390 obese patients (who have 2 or more components of the metabolic syndrome) by their own primary care providers, in conjunction with the practices' auxiliary health professionals, including medical assistants.

NCT ID: NCT00824395 Withdrawn - Type 2 Diabetes Clinical Trials

The Genetics of Diabetes in Southern California Chinese Americans

Start date: January 2006
Phase:
Study type: Observational

The purpose of this research study is to investigate the genetic causes of diabetes. Specifically, we are interested in the mitochondrial genome and how variants in the mitochondrial genome influence a person's risk to develop diabetes and metabolic syndrome.

NCT ID: NCT00823381 Completed - Obesity Clinical Trials

Effect of Resvida, a Comparison With Calorie Restriction Regimen

Resvida
Start date: January 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effects of the antioxidant "resveratrol" to a diet intervention (Calorie Restriction) to determine how each of them affects the following: gene expression profile, cholesterol (lipids), how well the hormone insulin works to control your blood sugar, and other blood and tissue markers of metabolic and cardiovascular health. Resveratrol is found in grape skin, wine, peanuts, and mulberries and is thought to have health benefits such as improving fat metabolism, insulin action, and possibly extending lifespan. Resvida™ is the name for the dietary supplement containing the natural antioxidant "resveratrol". Resvida™ will be supplied by DSM Nutritional Products, Ltd. Resvida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The makers of Resvida™ make no claim that this supplement is meant to treat any ailment. Calorie restriction (CR) is a low calorie diet (about 30% fewer calories than the American Dietetic Association (ADA) recommends). Calorie restriction has also been linked to health benefits (enhanced cardiovascular and metabolic health) and an extended lifespan. This study is designed to compare the health benefits of both resveratrol and CR and to determine if resveratrol mimics some of the health benefits shown with CR.

NCT ID: NCT00823277 Completed - Hypertension Clinical Trials

Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight

Start date: January 2009
Phase:
Study type: Observational

Definition: the overall objective is to examine childhood obesity with focus on NAFLD and its treatment. Further, we aimed to investigate the impact of genetic variation on obesity. The specific aims are to; - describe the degree of NAFLD among overweight and obese, Danish children. (hypothesis; the degree for pediatric NAFLD among Danish Children was equal that found in other Caucasian paediatric study populations). - investigate the effect of a multidisciplinary intervention treatment of 1 year on liver fat content. (hypothesis; the intervention could reduce the liver fat percentage and a reduction in BMI SDS would associate with a reduction in liver fat content) - Analyze changes in liver fat content in relation to changes in levels of fasting blood variables to see if any of them could be used as a clinical tool for monitoring hepatic steatosis in the clinic. (hypothesis; serum aminotransferases (separately and their ratio, respectively), serum insulin, and HOMA-IR could predict improvement in liver fat content - Investigate the association between genetic variants and obesity.

NCT ID: NCT00819403 Completed - Metabolic Syndrome Clinical Trials

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

Start date: January 2009
Phase: Phase 4
Study type: Interventional

To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.

NCT ID: NCT00817843 Completed - Metabolic Syndrome Clinical Trials

The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study

PANACEA
Start date: April 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate whether low-dose simvastatin in combination with ezetimibe in comparison to high-dose simvastatin alone, has a beneficial effect on the function of the endothelium after an oral fat load in patients with metabolic syndrome.

NCT ID: NCT00815659 Completed - Metabolic Syndrome Clinical Trials

Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

EFFORT
Start date: December 2008
Phase: Phase 4
Study type: Interventional

The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.

NCT ID: NCT00810290 Completed - Metabolic Syndrome Clinical Trials

Lawrence Latino Diabetes Prevention Project

LLDPP
Start date: July 2004
Phase: N/A
Study type: Interventional

The Lawrence Latino Diabetes Prevention Project (LLDPP) is a community-based translational research study which aims to reduce the risk of diabetes among Latinos who have a >30% probability of developing diabetes in the next 7.5 years per a predictive equation. The project was conducted in Lawrence, Massachusetts; a predominantly Caribbean-origin urban Latino community. Individuals were identified primarily from a community health center's patient panel, screened for study eligibility, randomized to either a usual care or a lifestyle intervention condition, and followed for one year.

NCT ID: NCT00808158 Completed - Metabolic Syndrome Clinical Trials

Examining the Relationship Between Tobacco Exposure, Abdominal Obesity, and Metabolic Syndrome in Adolescents (The STRONG Kids Study)

STRONG Kids
Start date: October 2008
Phase: N/A
Study type: Observational

Metabolic syndrome is a term that describes a group of conditions that increase the risk of cardiovascular disease. The conditions include high blood pressure, obesity, and high cholesterol. This study will examine how changes in tobacco exposure and weight can affect the risk of developing metabolic syndrome among adolescents.